Diplomat Pharmacy, Inc. (DPLO) Stake Lessened by State of Wisconsin Investment Board

State of Wisconsin Investment Board cut its holdings in shares of Diplomat Pharmacy, Inc. (NYSE:DPLO) by 18.0% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 228,000 shares of the company’s stock after selling 50,000 shares during the period. State of Wisconsin Investment Board owned 0.34% of Diplomat Pharmacy worth $4,722,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. JPMorgan Chase & Co. increased its position in shares of Diplomat Pharmacy by 73.1% during the first quarter. JPMorgan Chase & Co. now owns 7,235 shares of the company’s stock worth $116,000 after purchasing an additional 3,056 shares in the last quarter. State of Alaska Department of Revenue increased its position in shares of Diplomat Pharmacy by 80.0% during the second quarter. State of Alaska Department of Revenue now owns 8,623 shares of the company’s stock worth $127,000 after purchasing an additional 3,833 shares in the last quarter. PNC Financial Services Group Inc. increased its position in shares of Diplomat Pharmacy by 46.7% during the second quarter. PNC Financial Services Group Inc. now owns 8,779 shares of the company’s stock worth $130,000 after purchasing an additional 2,794 shares in the last quarter. Municipal Employees Retirement System of Michigan increased its position in shares of Diplomat Pharmacy by 4.9% during the second quarter. Municipal Employees Retirement System of Michigan now owns 10,250 shares of the company’s stock worth $152,000 after purchasing an additional 480 shares in the last quarter. Finally, Janney Montgomery Scott LLC increased its position in shares of Diplomat Pharmacy by 11.9% during the second quarter. Janney Montgomery Scott LLC now owns 11,193 shares of the company’s stock worth $166,000 after purchasing an additional 1,193 shares in the last quarter. 67.74% of the stock is currently owned by institutional investors and hedge funds.

A number of equities analysts have recently issued reports on the company. Robert W. Baird downgraded Diplomat Pharmacy from an “outperform” rating to a “neutral” rating and reduced their price target for the stock from $24.00 to $18.00 in a research report on Thursday, November 16th. BidaskClub downgraded Diplomat Pharmacy from a “buy” rating to a “hold” rating in a research report on Thursday, November 9th. Needham & Company LLC upped their target price on Diplomat Pharmacy from $23.75 to $24.00 and gave the company a “buy” rating in a research report on Wednesday, November 8th. Leerink Swann upped their target price on Diplomat Pharmacy from $16.00 to $20.00 and gave the company a “market perform” rating in a research report on Tuesday, November 7th. Finally, Mizuho upped their target price on Diplomat Pharmacy from $16.00 to $20.00 and gave the company a “neutral” rating in a research report on Tuesday, November 7th. One investment analyst has rated the stock with a sell rating, six have given a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $19.39.

In other news, CFO Atul Kavthekar bought 2,000 shares of the stock in a transaction dated Monday, November 20th. The shares were acquired at an average cost of $15.00 per share, with a total value of $30,000.00. Following the purchase, the chief financial officer now directly owns 2,000 shares in the company, valued at approximately $30,000. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, President Joel Saban bought 10,000 shares of the stock in a transaction dated Monday, November 20th. The shares were purchased at an average cost of $15.24 per share, for a total transaction of $152,400.00. Following the completion of the purchase, the president now owns 12,000 shares in the company, valued at $182,880. The disclosure for this purchase can be found here. Corporate insiders own 30.20% of the company’s stock.

Shares of Diplomat Pharmacy, Inc. (DPLO) opened at $15.94 on Tuesday. Diplomat Pharmacy, Inc. has a 1-year low of $12.25 and a 1-year high of $21.99. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.34 and a quick ratio of 0.82. The company has a market cap of $1,070.00, a price-to-earnings ratio of 19.48, a price-to-earnings-growth ratio of 2.70 and a beta of 0.74.

Diplomat Pharmacy (NYSE:DPLO) last posted its quarterly earnings results on Monday, November 6th. The company reported $0.25 EPS for the quarter, beating the consensus estimate of $0.15 by $0.10. Diplomat Pharmacy had a net margin of 0.18% and a return on equity of 8.30%. The company had revenue of $1.12 billion for the quarter, compared to analyst estimates of $1.16 billion. During the same period in the prior year, the company earned $0.21 earnings per share. The firm’s revenue was down 4.8% on a year-over-year basis. equities research analysts anticipate that Diplomat Pharmacy, Inc. will post 0.85 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This report was first published by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this report can be viewed at https://sportsperspectives.com/2017/11/21/diplomat-pharmacy-inc-dplo-stake-lessened-by-state-of-wisconsin-investment-board.html.

Diplomat Pharmacy Profile

Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.

Institutional Ownership by Quarter for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply